FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Reich Samuel J				2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [SABS]					(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Image: Imag						
(Last) 777 W 4		First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/15/2024						below)		Other (sbelow) 7E CHAIRM		
SUITE 401				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MIAMI	BEACH :	FL	33140											iled by More th	eporting Personan One Repo	
(City)	1	State)	(Zip)		Rule 10b5-1(c) Transaction Indication											
Check this box to indicate that a transaction was made pursuant to a contra satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction								n or written plar	n that is intende	d to						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date		Date,	Code (Instr. 5)		ed (A) or str. 3, 4 and	Beneficia	s Fo ally (D following (I)	rm: Direct	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy) ⁽¹⁾⁽²⁾	\$2.9	07/15/2024			A		35,700		(1)	07/15/2034	Common Stock	35,700	\$0	35,700	D	

Explanation of Responses:

- 1. Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028.
- 2. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

/s/ Samuel J. Reich

07/17/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.